Trial Profile
MARINER: phase III evaluation of rivaroxaban in the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism due to a concurrent disease.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Apr 2014
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Registrational; Therapeutic Use
- Acronyms MARINER
- 02 Apr 2014 New trial record